Amalgamated Bank Has $12.57 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Amalgamated Bank lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,404 shares of the medical instruments supplier’s stock after selling 1,364 shares during the period. Amalgamated Bank’s holdings in Becton, Dickinson and Company were worth $12,570,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Bank of Jackson Hole Trust bought a new stake in Becton, Dickinson and Company during the 4th quarter worth $25,000. Sierra Ocean LLC bought a new stake in Becton, Dickinson and Company during the 4th quarter worth $29,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth $33,000. Tompkins Financial Corp grew its position in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Finally, Kennebec Savings Bank bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,544 shares of company stock worth $2,370,309 in the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.1 %

NYSE BDX opened at $230.14 on Wednesday. The business’s 50-day moving average price is $233.05 and its two-hundred day moving average price is $233.21. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The firm has a market capitalization of $66.08 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays boosted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.